Parent Company Rhegen Biotech's Personalized mRNA Cancer Vaccine Clinical Study Initiated
Recently, parent company Rhegen Biotech officially announced the initiation of clinical research for its personalized mRNA cancer vaccine (code name RH125). This study is an investigator-initiated exploratory clinical trial (IIT), co-sponsored and protocol-determined by Academician Xu Binghe and Director Chang Jianhua, aiming to preliminarily evaluate the safety, tolerability, and therapeutic effects of the personalized mRNA vaccine based on tumor neoantigens, either used alone or in combination with PD-1 inhibitors, in patients with advanced solid tumors.
The RH125 vaccine is a personalized mRNA therapeutic vaccine for cancer developed by Rhegen Biotech. Based on each patient's unique tumor gene mutations, it uses the company's self-developed AI algorithm to predict highly immunogenic neoantigens. Through the self-developed next-generation lipid nanoparticle (LNP) delivery system, these antigens are efficiently presented in the patient's body, activating neoantigen-specific T cells to achieve the goal of killing tumor cells and treating cancer.
Advanced solid tumor treatment has long faced challenges such as limited treatment options and poor prognosis. Personalized mRNA cancer vaccine technology represents the cutting-edge direction of current cancer immunotherapy. Rhegen Biotech currently possesses leading technologies including artificial intelligence neoantigen prediction algorithms, mRNA nucleic acid delivery systems, and immune enhancement technologies. The initiation of this RH125 IIT study in patients with advanced solid tumors is expected to provide new treatment options for this patient population and improve their quality of life
News you may be interested in:
